Pseudomonas aeruginosa is widely attributed as the leading cause of hospital-acquired 22 infections. Due to intrinsic antibiotic resistance mechanisms, as well as the ability to form 23 biofilms, P. aeruginosa infections are notoriously difficult to treat. P. aeruginosa employs 24 multiple virulence mechanisms to establish infections, and the global virulence regulator, Vfr, 25 plays an important role in modulating these mechanisms. An attractive strategy to combat P. 26 aeruginosa infections is the use of anti-virulence compounds. Here, we report the identification 27 of auranofin, an FDA-approved drug, that attenuates virulence in P. aeruginosa. We present 28 evidence that auranofin exerts its action by targeting Vfr, which in turn leads to inhibition of 29 quorum sensing (QS), Type III secretion (T3SS) and Type IV pili (TFP). Consistent with potent 30 inhibition of QS and TFP expression, we show that auranofin attenuates biofilm maturation, 31 and when used in combination with colistin, displays strong synergy in eradicating P. 32 aeruginosa biofilms both in flow chambers and in a murine implant model. Auranofin may 33 have immediate applications as an anti-virulence drug against P. aeruginosa infections.
Introduction discovered to date. 81 82 In this work, we identified auranofin, an FDA-approved, gold(I)-based anti-83 inflammatory drug, as a potent inhibitor of virulence in P. aeruginosa. We show that auranofin 84 inhibits QS, T3SS and TFP formation at low micromolar concentrations. It does this in part by 85 targeting cysteines in Vfr and abolishing the ability of Vfr to bind DNA. Using flow cell biofilm 86 assays, we demonstrate that auranofin is able to attenuate biofilm maturation. Furthermore, 87 auranofin displays synergistic effects in eradicating P. aeruginosa biofilms in vitro, when used 88 in combination with colistin. We propose that auranofin can potentially be re-purposed as an 89 anti-virulent drug to treat P. aeruginosa infections.
Results

91
Auranofin inhibits QS in Pseudomonas aeruginosa 92 We initially discovered auranofin in a screen to identify small molecules that inhibit 93 QS in P. aeruginosa. We screened ~6,000 compounds from various libraries using a lasB-94 gfp(ASV) strain 35 , where expression of a fusion construct between LasB N-terminus and an 95 unstable GFP variant (GFP(ASV)) is controlled by constitutively expressed LasR, the cognate 96 transcriptional regulator of the las pathway. Inhibitors of this pathway should reduce GFP 97 fluorescence in this assay. In addition, since the las pathway controls both the rhl and pqs 98 pathways, compounds identified in this screen could potentially shut down the entire QS 99 network. We found that auranofin exhibits sub-micromolar (IC 50 ) inhibition of LasB-GFP 100 expression with minimal effects on cell growth (Fig. 1a , S1). Auranofin also strongly inhibits 101 fluorescence in two other reporter strains, rhlA-gfp(ASV) and pqsA-gfp(ASV) 36 , both under 102 the control of their respective transcriptional activators, RhlR and PqsR (Fig. 1b&c ). To 103 validate our findings, we examined the effects of auranofin on the levels of RNA transcripts 104 for key QS-regulated genes, as well as on the production of various QS-controlled virulence Auranofin inhibits expression of Type III secretion system (T3SS) and Type IV pili (TFP) 110 in P. aeruginosa 111 To gain insights into the mechanism(s)-of-action of auranofin, we compared the protein 112 profiles of P. aeruginosa in the presence and absence of auranofin. Consistent with it being a 113 QS inhibitor, treatment with auranofin caused reduction in the levels of proteins involved in or 114 regulated by QS (Table S1 ). Interestingly, we also observed down-regulation of proteins 115 involved in T3SS and TFP formation. We confirmed that T3SS was down-regulated using 116 immunoblot analyses ( Fig. S4 ). We also showed that auranofin is able to inhibit TFP-dependent 117 motility, including swarming and twitching 37,38 ( Fig. 3 ). Our observations here are, in part, due 118 to transcriptional down-regulation of these systems (Fig. S2 ). These results imply that 119 auranofin either has multiple targets, and/or it targets a transcriptional regulator upstream of 120 QS, T3SS and TFP. directly targets Vfr function. To test this, we examined the ability of auranofin to inhibit the 125 function of Vfr in binding to promoter sequences in vitro using electrophoretic mobility shift 126 assays (EMSA). We first showed that purified Vfr is able to bind DNA fragments containing 127 the promoter regions of representative QS (lasR) and virulence (toxA, regA) genes ( Fig. S3 ), 128 as previously reported 39 . We further demonstrated that auranofin effectively prevents Vfr 129 binding to these promoters in a dose-dependent manner, indicating that it inhibits Vfr function 130 in vitro (Fig. 4a, c & d) . Gold(I)-based compounds are thiophilic, and auranofin has previously 131 been shown to react covalently with cysteine residues within target proteins 40, 41 . To ascertain 132 if its inhibition of Vfr proceeded via covalent modification of cysteines, we generated a 133 cysteine-less Vfr variant (VfrD5) in which all five cysteines were replaced by serine residues.
134
This variant is functional as judged by its ability to bind the lasR, toxA and regA promoters in 135 vitro ( Fig. S3 ). Remarkably, auranofin is no longer able to prevent binding of VfrD5 to these 136 same promoters (Fig. 4b, c & d) . These results establish that auranofin inhibits Vfr in vitro via 137 its cysteine residues.
138
To determine if Vfr is the main target of auranofin in cells, we complemented the Dvfr 139 strain with wild-type Vfr and the VfrD5 variant, and examined the levels of elastase, T3SS expression and twitching motility in the presence and absence of auranofin. Both wild-type Vfr 141 and the VfrD5 variant were able to complement the Dvfr strain in these assays (Fig. S4 ). We 142 showed that auranofin inhibits all three phenotypes in the wild-type Vfr complemented strain, 143 as expected. Surprisingly, auranofin was still able to inhibit these phenotypes in the VfrD5 initial surface attachment of cells, as well as for the organization of cells into the typical 151 "mushroom" architecture of mature P. aeruginosa biofilms. QS is also critical for biofilm 152 maturation, although the mechanisms here are less understood. Since auranofin inhibits both 153 TFP formation and QS networks, we expect it to also have an impact on the development of P. 154 aeruginosa biofilms. To test this, we monitored biofilm formation and maturation in the 155 presence and absence of auranofin over a period of 72 h in continuous flow chambers. The 156 formation of fully matured, canonical mushroom-shaped biofilm structures for wild-type P.
Auranofin exhibits synergistic effects with colistin in killing P. aeruginosa biofilms 166 Since auranofin affects the maturation of the biofilm, we asked whether it may display 167 synergy with colistin, a last resort drug commonly used to treat P. aeruginosa infections. We with the exception of several surviving colistin-tolerant subpopulations 44 (Fig. 6a ).
172
Remarkably, adding auranofin prior to biofilm formation allows subsequent colistin additions 173 to completely eradicate the P. aeruginosa biofilm. In fact, co-treatment of a 2-day biofilm with 174 auranofin and colistin also results in complete killing. These results demonstrate synergy 175 between auranofin and colistin in a flow cell biofilm.
176
To test whether auranofin and colistin can work together in vivo, we surgically inserted silicone 177 implants coated with 1-day old P. aeruginosa biofilms into the peritoneal cavity of mice, and 178 subsequently treated them locally with colistin, auranofin, or a combination of both drugs.
179
Remarkably, combination therapy of auranofin and colistin resulted in significantly lower 180 bacterial titer counts from the implant than either auranofin or colistin alone (Fig. 6b ). This 181 confirms the synergy between auranofin and colistin in a murine model.
182
Discussion
183
Auranofin is approved by the FDA for the treatment of rheumatoid arthritis. It has been 184 shown to reduce inflammation of joints in rheumatic patients 45 ; however, the precise 185 mechanism of how this occurs is not clear. Auranofin also exhibits anti-cancer and anti-186 parasitic properties 40,46,47 . Furthermore, auranofin is able to kill a broad spectrum of Gram-187 positive bacteria, and also mycobacteria 41 . All of these activities may be attributed to expressing cysteine-less Vfr, suggesting that it has multiple targets in cells. This is probable, 199 given that auranofin is a general thiol-targeting reagent 40 . Understanding the mechanism of 200 action of auranofin would require identifying these unknown targets. to its toxicity 50 . We have shown that auranofin and colistin combine synergistically to 208 completely eradicate a P. aeruginosa biofilm, something not observed with colistin treatment 209 alone. This synergy is also observed in a murine implant model. We believe that the synergy 210 between auranofin and colistin works in both directions. It has been shown that disrupting outer 211 membrane permeability (here with the use of colistin) allows auranofin to penetrate the cell 212 envelope and kill Gram-negative bacteria, through its potential action on thioredoxin reductase. already an FDA-approved drug, it may not be in the very far future that this approach can be 218 tested.
219
Materials and Methods
220
Detailed methods can be found in SI Appendix, Materials and Methods. All bacterial strains 221 and plasmids are summarized in Table S2 and S3. Oligonucleotides for PCR are listed in Table   222 S4. 
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Figure Legends
